Lowy’s AACR keynote: “Unacceptable” disparities in cancer outcomes mar 21st century progress

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Drawing on Charles Dickens, NCI Acting Director Douglas Lowy has a teaching moment for oncology: we live in the best of times as well as the worst of times, because only fragments of human society—both in the United States and in low- and middle-income countries—fully benefit from modern cancer care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login